A new method to treat persistent corneal erosions after high-risk keratoplasty

Purpose: to compare the effectiveness of conventional preserved amnion and amnion saturated with platelet-rich (PRP) plasma lysate for the treatment of persistent corneal erosions (PCE) after high-risk keratoplasty.
Materials and methods. 40 patients with persistent corneal erosions after high-risk penetrating keratoplasty, followed up for 12 months, were divided into two clinical groups of 20 people each. The main group of patients, aged 34 to 84, received Flexamer amniotic membrane + PRP lysate, while the comparison group, aged 41 to 80, received Flexamer amniotic membrane only. Amniotic membrane coating was used in persistent corneal erosions of penetrating keratoplasty after unsuccessful conservative treatment. The amnion was sewn 2 mm from the limb with a continuous suture and covered with a soft contact lens. As a source of platelets, we used the blood of healthy volunteers, from which platelet-rich plasma with platelet concentration of over 1000 thousand/µl was taken, which was then frozen at -40 °C and defrosted at 0…4 °C to obtain PRP lysate. The criteria for evaluating the effectiveness of both groups were the times of epithelialization, the number of amniotic membrane coatings, and the number of preserved transplants at the end of the follow-up.
Results. Lyophilized amniotic membrane saturated with autologous PRP lysate growth factors was shown to be biocompatible. It was found to be safe for the patients, to reduce the epithelialization time, to reduce the number of operations required to cover the PÑE with the amnion, and to increase the likelihood of successful transparent and translucent engraftment of a penetrating keratograft.
Conclusion. The use of a lyophilized amniotic membrane enriched with growth factors of autologous PRP lysate is a promising method for the treatment of PCE of the penetrating corneal graft after high-risk keratoplasty.

1. Slonimsky A.Yu., Slonimsky Yu.B., Dolgiy S.S. End-to-end corneal transplanta tion in purulent processes of the anterior segment of the eyeball. Russian journal of clinical ophthalmology. 2010; 11 (1): 11–4 (In Russ.).

2. Trufanov S.V., Subbot A.M., Malozhen S.A., Krakhmaleva D.A. Hypothesis of immune privilege of the cornea and pathophysiology of graft rejection. Vestnik oftalmologii. 2016; 132 (5): 117–24 (In Russ.). doi: 10.17116/oftalma20161325117-124

3. Thompson JrRW, Price MO, Bowers PJ, Price FWJr. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003; 110 (7): 1396–402. doi: 10.1016/S0161-6420 (03)00463-9

4. Malyugin B.E., Sakhnov S.N., Myasnikova V.V., et al. Corneal graft survival analysis after penetrating keratoplasty in a retrospective cohort study. Fyodorov Journal of Ophthalmic Surgery. 2021; 4: 12–20 (In Russ.). https:/doi.org/10.25276/0235-4160-2021-4-12-20

5. Khazamova A.I., Chentsova E.V., Kugusheva A.E., Slepova O.S., Makarov P.V. Persistent erosion of the corneal graft: analysis of causes, surgical methods of treatment and prevention. Point of view. East-West. 2016; (3): 28–31 (In Russ.).

6. Tseng SC. Amniotic membrane transplantation for ocular surface reconstruction. 2001; 21 (4): 481–9. doi: 10.1023/a:1017995810755

7. Twiford JD, Trelford-Sauder M. The amnion in surgery, past and present. Am J Obstet Gynecol. 1979; 134 (7): 833–45. doi 10.1016/0002-9378(79)90957-8

8. Tseng SC, Prabhasawat P, Barton K, Gray T, Meller D. Amniotic membran transplant with or without limbal allograft corneal surface reconstruction in pathients with limbal stem cell deficiency. Arch Ophthalmol. 1998; 116 (4): 431–41. doi: 10.1001/archopht.116.4.431

9. Gupta S, Paliczak A, Delgado D. Evidence-based indications of plateletrich plasma therapy. Expert Rev Hematol. 2021; 14 (1): 97–108. doi: 10.1080/17474086.2021.1860002

10. Chentsova E.V., Borovkova N.V., Bozhenko D.A., et al. A method of surgical treatment of corneal defects of various genesis. Patent RU 2782129; 2022 (In Russ.).

11. Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013; 4 (3): 67. doi: 10.1186/scrt218

12. Borovkova N.V., Makarov M.S., Andreev Yu.V., Storozheva M.V., Ponomarev I.N. Evaluation of the cytokine composition of blood serum and drugs based on human platelets. Malekulyarnaya medicina. 2021; 19 (3). 51–7 (In Russ.). doi: 10.29296/24999490-2021-03-08

13. Makarov M.S., Storozheva M.V., Konyushko O.I., Borovkova N.V., Khvatov V.B. Effect of concentration of platelet-derived growth factor on proliferative activity of human fibroblasts. Kletochny`e texnologii v biologii i medicine. 2013; 155 (4): 576–80 (In Russ.). doi: 10.1007/s10517-013-2199-9

14. Borovkova N.V., Makarov M.S., Storozheva M.V., Ponomarev I.N. Method for preparing platelet lysate with a high content of growth factors. Patent RU 2739515C1; 2020 (In Russ.).

15. Chentsova E.V., Borovkova N.V., Makarov P.V., et al. The biological effect of a combination of platelet lysate and amniotic membrane in buccal epithelium culture. Russian ophthalmological journal. 2022; 15 (4): 115–20 (In Russ.). doi. 10.21516/2072-0076-2022-15-4-115-120

16. Bozhenko D.A., Chentsova E.V., Borovkova N.V., et al. The use of platelet lysate to increase the growth-stimulating effect of the amniotic membrane in vitro. Ophthalmologicheskie vedomosti. 2022; 15 (3): 57–62 (In Russ.). https://doi.org/10.17816/OV108704